|
Early Modelling
Economic evaluations are increasingly used as tools to inform decision-makers about the cost-effectiveness of health technologies. Such evaluations are often undertaken during the late stages of the technology development (i.e. around the time of product launch or, in some cases, post-launch). However, there is an increasing need for the manufacturers of the technology to appraise the likely cost-effectiveness of the intervention before making decisions on price and indication, as well as to inform the development of clinical trials.
Early models can be performed in the very early stages of a technology’s development, (e.g. phase I or II). Due to the simplified nature of such ‘early analyses’, there is no requirement for Phase III trial data, or subtle interactions between parameters. The purposes of such an analysis are to allow the user to determine the relative importance of different parameter inputs, in order to inform decisions on pricing, target populations and further research.
Over recent years YHEC has built up a team of researchers with expertise in delivering high quality early stage modelling. We also run regular specialised training courses in the methods of early modelling.
Some of our recent publications are:
Bagust A, Schoeffski O, Shearer A, Goertz A, Reitberger U, Behrens M. The DiDACT economic model of type 2 diabetes for Germany Diabetes und Stoffwechsel 2003; 12(Suppl 1): 159.  Gordois A, Scuffham PA, Shearer A, Oglesby A. The costs and consequences of peripheral neuropathy in the UK The Diabetic Foot 2003; 6(1): 30-37.
For more details please contact Dr Matthew Taylor (Project Director, Pharmacoeconomics) by telephone (+44 (0) 1904 323631) or email (matthew.taylor@york.ac.uk)
|
